Hepatitis C Drugs – A Look at Emerging Payment Models and Patient-Centered Outcomes Research
May 15, 2019. . Sponsored by National Academy for State Health Policy
Is liver stiffness measured by MRE useful for predicting HCC development in patients with chronic hepatitis C who achieved SVR following DAA treatment?Journal of Viral Hepatitis
In conclusion, until better noninvasive markers for liver fibrosis are developed and validated for HIV-HCV coinfected patients, noninvasive serum markers should be used carefully in this population. PMID: 31320163 [PubMed]
Authors: Quarleri JF, Oubiña JR Abstract Hepatitis C virus (HCV) is a small, enveloped RNA virus. The number of HCV-infected individuals worldwide is estimated to be approximately 200 million. The vast majority of HCV infections persist, with up to 80% of all cases leading to chronic hepatitis associated with liver fibrosis, cirrhosis, and hepatocellular carcinoma. The interaction between HCV and the host have a pivotal role in viral fitness, persistence, pathogenicity, and disease progression. The control of HCV infection requires both effective innate and adaptive immune responses. The HCV clearance during...
Authors: Villar LM, Lampe E, de Almeida AJ, de Paula Scalioni L, Lewis-Ximenez LL, Miguel JC, Del Campo JA, Ranchal I, Villela-Nogueira CA, Romero-Gomez M PMID: 31320161 [PubMed]
Authors: Basyigit S, Sapmaz F, Kefeli A PMID: 31320160 [PubMed]
In this study, we took advantage of the high prevalence of pharmacologically induced depression in patients treated with IFN-α and ribavirin to test the interest of RNA editing–related biomarkers in white blood cells of patients. In this 16-week longitudinal study, a small cohort of patients was clinically evaluated using standard assessment methods prior to and during antiviral therapy and blood samples were collected to analyse RNA editing modifications. A-I RNA editing activity on the phosphodiesterase 8A (PDE8A) gene, a previously identified RNA editing hotspot in the c ontext of lupus erythematosus, was qu...
Publication date: Available online 19 July 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Suresh Gorka, Ghulam Mohd Gulzar, Ghulam Nabi Yattoo, Jaswinder Singh Sodhi, Gulzar Ahmad Dar, Mushtaq Ahmad Laway, Saurabh Kaushik, Neeraj Dhar, Syed Mushfiq, Riffat Abdul AzizAbstractBackground/ObjectiveOur data is one of the earliest study from Indian subcontinent on Velpatasvir/Sofosbuvir (VEL/SOF) combination in chronic hepatitis C (CHC). The primary end point was to evaluate the sustained virologic response (SVR-12) in CHC infected patients and to determine its effect in patients with HCV related cirrhosis...
In conclusion, aberrantly methylated AURKA and FOS may be potential therapeutic targets for HCV‑positive HCC. PMID: 31322223 [PubMed - as supplied by publisher]
Conclusions: Pretreatment characteristics differentially predict treatment response for heroin and cocaine use. Similar research in diverse patient groups may aid in the development of personalized treatment combining biologic treatment with targeted psychosocial interventions. PMID: 31315479 [PubMed - as supplied by publisher]